PMD-026 Reduces Triple Negative Breast Cancer Growth, Mice Study Shows

PMD-026 Reduces Triple Negative Breast Cancer Growth, Mice Study Shows
PMD-026 reduced tumor growth in mice with triple negative breast cancer (TNBC), according to its developer, Phoenix Molecular Designs. The therapy, which targets the RSK family of enzymes associated with cancer progression, was also safe, the company said. TNBC is difficult to treat, not only because it behaves differently from patient to patient, but also because no therapies are effective against it. PhoenixMD used genome screening to identify RSK, or p90 ribosomal S6 kinase, as a good target for TNBC therapies. The RSK family consists of four enzymes involved in cancer development. They are key regulators of cancer cell invasion and growth, but they are also associated with cancer cell drug resistance. About 90 percent of TNBC cases are associated with abnormally high levels of two of the enzymes, RSK1 and RSK2. That suggests that the cancer cells rely on the enzymes' activity for survival and proliferation. In fact, chemically inhibiting RSK2 in a lab killed TNBC cells and the cancer stem cells responsible for cancer recurring. "The need for new targeted therapies to help patients suffering with TNBC is urgent, but unfortunately novel treatments are extremely scarce," Sandra Dunn, chief executive officer of PhoenixMD, said in a press release. "We are addressing this unmet medical need through a novel, targeted approach by inhibiting critical kinases, such as RSK, known to be involved in the progression of numerous" cancers. Researchers tested PMD-026 for 28 days in mice with drug-resistant TNBC. The drug lowered RKS's activity b
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.